Claims

1. An aqueous pharmaceutical composition comprising about 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, about 5.8% (w/v) sucrose, 10 mM sodium citrate, and 0.02% (w/v) polysorbate 80, wherein the pH of the composition is 7.2, and wherein the composition does not have an increase in particulate matter counts greater than 10 microns after three days of shaking stress.

2. The aqueous pharmaceutical composition according to claim 1, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 or 4.

3. The aqueous pharmaceutical composition according to claim 1, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 and 4.

4. The aqueous pharmaceutical composition of claim 1, comprising 120 mg/ml of the anti-VEGF antibody.

5. The aqueous pharmaceutical composition of claim 1, comprising 5.8% (w/v) sucrose.

6. The aqueous pharmaceutical composition of claim 1, comprising 3 mg of the anti-VEGF antibody.

7. The aqueous pharmaceutical composition of claim 1, comprising 6 mg of the anti-VEGF antibody.

8. The aqueous pharmaceutical composition of claim 1, wherein said composition is liquid.

9. A delivery device comprising the aqueous pharmaceutical composition of claim 1.

10. The delivery device of claim 9, which is a pre-filled syringe.